Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma.
Charalampous C, Goel U, Broski SM, Dingli D, Kapoor P, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi F, Hwa L, Leung N, Lin Y, Gonsalves WI, Kourelis TV, Warsame R, Fonder A, Hobbs M, Binder M, Kyle RA, Rajkumar SV, Kumar SK. Charalampous C, et al. Among authors: goel u. Blood Adv. 2022 May 10;6(9):2763-2772. doi: 10.1182/bloodadvances.2022007052. Blood Adv. 2022. PMID: 35235951 Free PMC article.
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar S. Charalampous C, et al. Among authors: goel u. Am J Hematol. 2023 Mar;98(3):413-420. doi: 10.1002/ajh.26806. Epub 2023 Jan 1. Am J Hematol. 2023. PMID: 36588396 Free article.
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Charalampous C, et al. Among authors: goel u. Blood Adv. 2023 Aug 22;7(16):4371-4380. doi: 10.1182/bloodadvances.2023009681. Blood Adv. 2023. PMID: 37603349 Free PMC article.
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide.
Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame RM, Kyle RA, Rajkumar SV, Kumar SK. Goel U, et al. Blood Cancer J. 2024 Mar 26;14(1):55. doi: 10.1038/s41408-024-01039-1. Blood Cancer J. 2024. PMID: 38531841 Free PMC article.
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
Dima D, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, DeJarnette S, Anwer F, Shune L, Raza S, Mahmoudjafari Z, Williams L, Faiman B, McGuirk JP, Sauter CS, Ahmed N, Khouri J, Hashmi H. Dima D, et al. Among authors: goel u. Blood Cancer J. 2024 May 31;14(1):90. doi: 10.1038/s41408-024-01068-w. Blood Cancer J. 2024. PMID: 38821914 Free PMC article.
47 results